Numerous Therapeutic options are currently available to treat Multiple Sclerosis (MS). MS is an autoimmune inflammatory disorder mainly determined by axonal demyelination even at the early stages of the disease.

Indeed, the axonal damage occurs both within visible lesions and in the normal-appearing white matter, as demonstrated by MRI scans and by the use of biomarkers. Extended and progressive lesions may generate irreversible neurological deficits with frequent relapse of the disease and Disability Progression. Even if the mechanistic role of the immune system in MS has been not elucidated yet, the majority of so called disease-modifying treatments (DMTs) in MS have been designed to modulate it and are almost exclusively effective when the disease is in the active phases in which the inflammatory component is prominent.

Other drugs prevent lymphocytes migration across the blood- brain barrier, thus limiting the inflammatory response. In the last years, important advances in MS treatments have been made. Currently, therapeutic treatments can reduce the number of relapses per year and delay disability progression, thus ensuring a better quality of life for the majority of patients.

Early diagnosis may allow early and timely treatment which is critical in limiting neurological damages and in gaining the best clinical outcomes for patients. Multiple Sclerosis (MS) is slowly becoming less scary!